Rachael Sexton

2.3k total citations · 1 hit paper
32 papers, 1.4k citations indexed

About

Rachael Sexton is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Rachael Sexton has authored 32 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 15 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in Rachael Sexton's work include Multiple Myeloma Research and Treatments (24 papers), Protein Degradation and Inhibitors (14 papers) and Helicobacter pylori-related gastroenterology studies (5 papers). Rachael Sexton is often cited by papers focused on Multiple Myeloma Research and Treatments (24 papers), Protein Degradation and Inhibitors (14 papers) and Helicobacter pylori-related gastroenterology studies (5 papers). Rachael Sexton collaborates with scholars based in United States, Chile and Peru. Rachael Sexton's co-authors include Robert Z. Orlowski, Antje Hoering, Bart Barlogie, S. Vincent Rajkumar, Brian G.M. Durie, Angela Dispenzieri, Joshua Epstein, Muneer H. Abidi, Mohan C. Thakuri and Frederic J. Reu and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Rachael Sexton

30 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

2016 594 citations Brian G.M. Durie, Antje Hoering et al. The Lancet profile →

Peers

Countries citing papers authored by Rachael Sexton

Since Specialization

Citations

This map shows the geographic impact of Rachael Sexton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachael Sexton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachael Sexton more than expected).

Fields of papers citing papers by Rachael Sexton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachael Sexton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachael Sexton. The network helps show where Rachael Sexton may publish in the future.

Co-authorship network of co-authors of Rachael Sexton

This figure shows the co-authorship network connecting the top 25 collaborators of Rachael Sexton. A scholar is included among the top collaborators of Rachael Sexton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachael Sexton. Rachael Sexton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis 2024 ·Blood ·Rahul Banerjee, Rachael Sexton, (unknown), Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji Kumar, Angela Dispenzieri, Sagar Lonial, B G M Durie, Paul G. Richardson, Saad Z. Usmani, Antje Hoering, Robert Z. Orlowski	3
2	Title Pending 371 2024 ·PubMed ·(unknown), Chad Cook, (unknown), Sunita Yadav, Dinesh Pal Mudaranthakam, Rachael Sexton, (unknown), Leslie Garcia, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Antje Hoering, Michael LeBlanc, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
3	Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211 2023 ·Blood ·Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji Kumar, Sagar Lonial, Bart Barlogie, Brian G.M. Durie, Saad Z. Usmani, Antje Hoering, Robert Z. Orlowski	1
4	Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial 2020 ·The Lancet Haematology ·Saad Z. Usmani, Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, (unknown), Jason Valent, Michael Rosenzweig, Jeffrey A. Zonder, Madhav V. Dhodapkar, Natalie S. Callander, Todd M. Zimmerman, Peter M. Voorhees, Brian G.M. Durie, S. Vincent Rajkumar, Paul G. Richardson, Robert Z. Orlowski	80
5	Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma 2020 ·Clinical Cancer Research ·Sikander Ailawadhi, Rachael Sexton, Suzanne Lentzsch, Muneer H. Abidi, Peter M. Voorhees, Adam D. Cohen, Eric Rohren, Stephen B. Heitner, Kevin R. Kelly, (unknown), David Baer, Antje Hoering, Brian G.M. Durie, Robert Z. Orlowski	11
6	Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) 2020 ·Blood Cancer Journal ·Brian G.M. Durie, Antje Hoering, Rachael Sexton, Muneer H. Abidi, Joshua Epstein, S. Vincent Rajkumar, Angela Dispenzieri, Stephen P. Kahanic, Mohan C. Thakuri, Frederic J. Reu, Christopher M. Reynolds, Robert Z. Orlowski, Bart Barlogie	139
7	Race-Dependent Differences in Risk, Genomics, and Epstein–Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120 2020 ·Clinical Cancer Research ·Madhav V. Dhodapkar, Rachael Sexton, Antje Hoering, Frits van Rhee, Bart Barlogie, Robert Z. Orlowski	7
8	Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803 2020 ·Blood ·Amrita Krishnan, Antje Hoering, Parameswaran Hari, Rachael Sexton, Robert Z. Orlowski	16
9	Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials 2018 ·Blood Cancer Journal ·Sikander Ailawadhi, Susanna Jacobus, Rachael Sexton, Alexander K. Stewart, Angela Dispenzieri, Mohamad A. Hussein, Jeffrey A. Zonder, John Crowley, Antje Hoering, Bart Barlogie, Robert Z. Orlowski, S. Vincent Rajkumar	59
10	Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT) 2018 ·Blood ·Brian G.M. Durie, Antje Hoering, Rachael Sexton, Muneer H. Abidi, Joshua Epstein, S. Vincent Rajkumar, Angela Dispenzieri, Stephen P. Kahanic, Mohan C. Thakuri, Frederic J. Reu, Christopher M. Reynolds, Robert Z. Orlowski, Bart Barlogie	21
11	Antibiotic resistance among <em>Helicobacter pylori</em> clinical isolates in Lima, Peru 2017 ·Infection and Drug Resistance ·Kevin F. Boehnke, Manuel Valdivieso, Alejandro Bussalleu, Rachael Sexton, (unknown), (unknown), (unknown), John J. Crowley, Laurence H. Baker, Chuanwu Xi	32
12	Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial breakdown → 2016 ·The Lancet ·Brian G.M. Durie, Antje Hoering, Muneer H. Abidi, S. Vincent Rajkumar, Joshua Epstein, Stephen P. Kahanic, Mohan C. Thakuri, Frederic J. Reu, Christopher M. Reynolds, Rachael Sexton, Robert Z. Orlowski, Bart Barlogie, Angela Dispenzieri	594
13	Disease and Outcome Disparities in Multiple Myeloma (MM): Exploring the Role of Race/Ethnicity and Obesity in Cooperative Group Clinical Trials 2016 ·Blood ·Sikander Ailawadhi, Susanna Jacobus, Rachael Sexton, A. Keith Stewart, Angela Dispenzieri, Mohamad A. Hussein, Jeffrey A. Zonder, John Crowley, Antje Hoering, Bart Barlogie, Robert Z. Orlowski, S. Vincent Rajkumar	2
14	SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM) 2014 ·Blood ·Saad Z. Usmani, Rachael Sexton, Sikander Ailawadhi, Jatin J. Shah, Natalie S. Callander, Todd M. Zimmerman, Jason Valent, Michael Rosenzweig, Brea Lipe, Jeffrey A. Zonder, (unknown), Brian G.M. Durie, Antje Hoering, S. Vincent Rajkumar, Paul G. Richardson, Robert Z. Orlowski	4
15	Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120) 2013 ·Blood ·Madhav V. Dhodapkar, Rachael Sexton, Sarah Waheed, Saad Z. Usmani, Xenofon Papanikolaou, Bijay Nair, Nathan Petty, John D. Shaughnessy, Antje Hoering, John Crowley, Robert Z. Orlowski, Bart Barlogie	123
16	Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701) 2012 ·Cancer Causes & Control ·Carolina Porras, Jesse Nodora, Rachael Sexton, Catterina Ferreccio, Silvia Jiménez, Ricardo L. Domínguez, Paz Cook, Garnet L. Anderson, Douglas R. Morgan, Laurence H. Baker, E. Robert Greenberg, Rolando Herrero	111
17	Su1673 H. pylori Recurrence One Year After Eradication Treatment in a Population Randomized Trial (SWOG S0701) in Seven Latin American Sites 2012 ·Gastroenterology ·Douglas R. Morgan, Javier Torres, E. Robert Greenberg, Rachael Sexton, Eduardo Salazar-Martı́nez, Ricardo L. Domínguez, Catterina Ferreccio, Luis Eduardo Bravo, Edgar M. Peña-Galo, Rolando Herrero, María Mercedes Meza‐Montenegro, María E. Martinez, Pelayo Correa, William D. Chey, Manuel Valdivieso, Garnet L. Anderson, Laurence H. Baker	1
18	Su1677 Risk Factors for Helicobacter pylori Infection in Six Latin American Countries (SWOG Trial S0701) 2012 ·Gastroenterology ·Carolina Porras, Jesse Nodora, Rachael Sexton, Ricardo L. Domínguez, Silvia Jiménez, Garnet L. Anderson, Rolando Herrero, Douglas R. Morgan, Laurence H. Baker, E. Robert Greenberg	1
19	Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol 2011 ·Blood ·Saad Z. Usmani, Jackie Szymonifka, Rachael Sexton, Susan Panozzo, Bijay Nair, Sarah Waheed, Yazan Alsayed, John Crowley, Bart Barlogie	4
20	Binding of <sup>14</sup>C-Salicylic Acid and <sup>14</sup>C-PentobarbitaI to Plasma Proteins of Several Species During the Perinatal Period 1975 ·Neonatology ·Charles R. Short, Rachael Sexton, (unknown)	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact